Eden Research plc Director/PDMR Shareholding (4541Z)
May 26 2016 - 9:36AM
UK Regulatory
TIDMEDEN
RNS Number : 4541Z
Eden Research plc
26 May 2016
Eden Research Plc
("Eden" or "Company")
Director/PDMR Shareholding
Eden Research plc (AIM: EDEN), the AIM-listed company that
provides breakthrough natural microencapsulation technologies to
the global agrochemicals, animal health and consumer products
industries, announces that Robin Cridland, Non-Executive Director,
today purchased 47,000 ordinary shares of 1 pence each in the
Company ("Ordinary Shares") at a price of 10.4 pence per share.
As a result of this transaction, Mr Cridland is interested in
47,000 Ordinary Shares in the Company, representing approximately
0.03 per cent of the issued share capital.
Eden also announces that Alex Abrey, Chief Financial Officer,
was yesterday granted 1,050,000 share options to purchase Ordinary
Shares at an exercise price of 13 pence with effect from the 25 May
2016 and an expiry date of 24 May 2021.
Eden Research plc www.edenresearch.com
Sean Smith, Chief Executive Officer Tel: 01285 359 555
Alex Abrey, Chief Financial Officer
Shore Capital and Corporate Limited www.shorecap.com
Stephane Auton/Patrick Castle Tel: 020 7408 4090
Walbrook PR Ltd Tel: 020 7933 8780 or eden@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
Notes:
Eden is an early stage revenue company with intellectual
property and expertise in encapsulation, terpenes and
environmentally friendly technologies to provide naturally
occurring solutions to the global agrochemicals industry, the
animal health industry, and consumer products.
Eden's encapsulation technology harnesses the biocidal efficacy
of naturally occurring chemicals produced by plants (terpenes) and
can also be used with both natural and synthetic hydrophobic
compounds. The technology uses yeast cells that are a by-product of
numerous commercial production processes to deliver a slow release
of natural compounds for agricultural and non-agricultural uses.
Terpenes are already widely used in the food flavouring, cosmetic
and pharmaceutical industries.
Historically, terpenes have had limited commercial use in the
agrochemical sector due to their volatility, phytotoxicity and poor
solubility. Eden's platform encapsulation technology provides a
unique, environmentally friendly solution to these problems and
enables terpenes to be used as effective, low-risk
agrochemicals.
With leading consultants in their respective fields, the Company
is developing these technologies through innovative research and a
series of commercial production, marketing and distribution
partnerships.
The Company has a number of patents and a pipeline of products
at differing stages of development targeting specific areas of the
global agrochemicals industry. To date, the Company has invested in
the region of GBP12m in developing and protecting its intellectual
property and seeking regulatory approval for products that rely
upon the Company's technologies. Revenues earned by the Company
have been modest whilst the Company has concentrated on securing
patent protection for its intellectual property, gaining regulatory
approvals, identifying suitable industrial partners, and entering
into licence agreements.
In May 2013, the three actives that comprise Eden's first
commercial product, 3AEY, were approved as new ingredients for use
in plant protection products. This represents a major milestone in
the commercialisation of Eden's technology and is a significant
accomplishment for any company. To illustrate this point, one
should note that in all of 2013, Eden's approvals represented 3 of
only 10 new active ingredients approved by the EC.
3AEY has already been authorised for sale in Kenya, Malta,
Greece, Bulgaria, Spain and Italy.
Eden was admitted to trading on AIM on 11 May 2012 and trades
under the symbol EDEN.
For more information about Eden, please visit:
www.edenresearch.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHSELFLMFMSEDI
(END) Dow Jones Newswires
May 26, 2016 10:36 ET (14:36 GMT)
Eden Research (LSE:EDEN)
Historical Stock Chart
From Apr 2024 to May 2024
Eden Research (LSE:EDEN)
Historical Stock Chart
From May 2023 to May 2024